Siamak Baharloo is a Boston-based entrepreneur who is a Doctor of Philosophy (Human/Medical Genetics) and CEO of Labviva, a SaaS company in the healthcare purchasing space. Baharloo founded the company in 2017 and raised significant funds from MassVentures, Village Global, Glasswing Ventures, and Tech Coast Angels. He is best known for his advocacy for platform tools for complex business such as biopharmaceutical research. Education and research Baharloo earned a B.A.S.c (B.A.Sc.) in Biochemistry and Molecular Biology from the University of Maryland, Baltimore County and a Ph.D. in genetics from the University of California, San Francisco. While at UCSF, he performed extensive genetic research and published papers on many of his findings, including work regarding Byler syndrome, intrahepatic cholestasis, and bipolar disorder His work remains well-cited. His graduate dissertation explored the genetic basis for perfect pitch and was based on a study of 500 musicians. Baharloo's work found evidence that the some of the ability to instantly recognize musical notes is inherited. Baharloo is the holder or co-holder of several patents related to the intersection of scientific protocols and commerce. Business career After working on a genetic mapping project that extensively leveraged technology, rather than staying in academia, Baharloo pursued a business career specializing in e-business and e-commerce for the healthcare industry. He worked for large healthcare organizations like Merck Group and Thermo Fisher Scientific in an executive capacity before going on to found his own company.
|